« Previous
Next »
Journal of the American College of Radiology
Volume 5, Issue 1
, Pages 53-56
, January 2008
Impact on Hospital Policy: Yale Experience
References
- . Renal lesion characterization with gadolinium-enhanced MR imaging: efficacy and safety in patients with renal insufficiency. Radiology. 1991;180:85–89
- Renal tolerance of gadolinium-DTPA dimeglumine in patients with chronic renal failure. Invest Radiol. 1992;27:153–156
- . Safety review of gadopentetate dimeglumine: extensive clinical experience after more than five million applications. Invest Radiol. 1994;29:S179–S182
- . Public health advisory: gadolinium-containing contrast agents for magnetic resonance imaging (MRI)—Omniscan, OptiMARK, Magnevist, ProHance, and MultiHance. http://www.fda.gov/cder/drug/advisory/gadolinium_agents.htmAccessed November 19, 2007
- . Gadolinium: a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?. Nephrol Dial Transplant. 2006;21:1104–1108
- . Investigation of the safety of MRI contrast medium Omniscan®. http://www.dkma.dk/1024/visUKLSArtikel.asp?artikelID=8931Accessed November 19, 2007
- State of Connecticut House Bill No. 5616. Public Act 06-120.
- Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000. J Am Soc Nephrol. 2005;16:180–188
- Prediction of GFR in liver transplant candidates. Am J Kidney Dis. 2003;42:1169–1176
PII: S1546-1440(07)00447-4
doi: 10.1016/j.jacr.2007.08.012
© 2008 American College of Radiology. Published by Elsevier Inc. All rights reserved.
« Previous
Next »
Journal of the American College of Radiology
Volume 5, Issue 1
, Pages 53-56
, January 2008
